Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension

被引:1
|
作者
Zhang, Jingsi [1 ]
Wang, Mingyu [1 ]
Sun, Kehui [1 ]
Ding, Yanchun [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dept Cardiol 2, Dalian, Peoples R China
关键词
ACEI; ARB; primary hypertension; renal dynamic imaging; split renal function; KIDNEY-DISEASE; BLOOD-PRESSURE; IRBESARTAN; MORTALITY;
D O I
10.1097/MD.0000000000025928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bilateral kidney damage in hypertensive patients is not parallel. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), as a commonly used antihypertensive drug, could protect kidney function and delay its deterioration. Most studies focused on overall renal function, but the researches on split renal function (SRF) are rare. We investigated the effects of ACEI/ARB on the SRF in patients with primary hypertension. Patients with primary hypertension (n = 429; male: 213; female: 216) admitted to our department between January 2014 and December 2016 were included in this study. The glomerular filtration rate (GFR) of split and total renal function were determined using diethylenetriaminepentaacetic acid tagged with 99mTc renal dynamic imaging method. For the same patient, the side with high GFR was considered as higher GFR kidney, whereas that with a low GFR was considered as lower GFR kidney. The split function score (Q value) was utilized to evaluate the differences of bilateral renal function. The patients were divided into 3 groups based on the Q values (Group 1, Q value <5%; Group 2, Q value of 5%-10%; Group 3, Q value >= 10%). All the patients received antihypertensive therapy based on ACEI/ARB. The renal dynamic imaging was performed in the 1-year follow-up to investigate the changes of the SRF. Compared with the baseline level, significant decline was noticed in the serum creatinine (Scr) in Group 2 and Group 3 (P < .05). The cystatin C in Group 3 showed significant decline (P < .05). Compared with the baseline, there was significant decline in the Q value in Group 2, whereas the GFR of lower GFR kidney showed significant increase (P < .05). No statistical differences were noticed in the Q value and split GFR in Group 1 and Group 3 (P > .05). In primary hypertension patients, ACEI/ARB therapy could improve the SRF of lower GFR kidney in the presence of certain differences between the SRF. As a result, the SRF difference was reduced. In case of Q value in a range of 5% to 10%, ACEI/ARB could improve the renal function effectively. It may be significant for the design of antihypertensive drugs.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 gender differences in fetal programmed hypertension
    Stone, Ryan
    Su, Yixin
    Rose, James C.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 204 : S207 - S208
  • [42] Alterations in Circulatory and Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Fetal Programmed Hypertension
    Shaltout, Hossam A.
    Figueroa, Jorge P.
    Rose, James C.
    Diz, Debra I.
    Chappell, Mark C.
    HYPERTENSION, 2009, 53 (02) : 404 - 408
  • [43] Polymorphism of angiotensin-converting enzyme in patients with primary glomerulonephritis and hypertension
    Kuzmanic, D
    Jelakovic, B
    Roncevic, T
    Borso, G
    Sertic, J
    Cvoriscec, D
    Laganovic, M
    Uhl, Z
    Vdovic, M
    JOURNAL OF HYPERTENSION, 1998, 16 : S56 - S56
  • [44] Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor
    d'Alessandro, Miriana
    Bergantini, Laura
    Perrone, Anna
    Cameli, Paolo
    Cameli, Matteo
    Prasse, Antje
    Plataroti, Dario
    Sestini, Piersante
    Bargagli, Elena
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 78 : 58 - 62
  • [45] Olmesartan is an angiotensin II receptor blocker with an inhibitory effect of angiotensin-converting enzyme
    Agata, Jun
    Ura, Nobuyuki
    Yoshida, Hideaki
    Shinshi, Yasuyuki
    Sasaki, Haruki
    Hyakkoku, Masaya
    Taniguchi, Shinya
    Shimamoto, Kazuaki
    JOURNAL OF HYPERTENSION, 2006, 24 : 208 - 208
  • [46] Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme
    Jun Agata
    Nobuyuki Ura
    Hideaki Yoshida
    Yasuyuki Shinshi
    Haruki Sasaki
    Masaya Hyakkoku
    Shinya Taniguchi
    Kazuaki Shimamoto
    Hypertension Research, 2006, 29 : 865 - 874
  • [47] Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme
    Agata, Jun
    Ura, Nobuyuki
    Yoshida, Hideaki
    Shinshi, Yasuyuki
    Sasaki, Haruki
    Hyakkoku, Masaya
    Taniguchi, Shinya
    Shimamoto, Kazuaki
    HYPERTENSION RESEARCH, 2006, 29 (11) : 865 - 874
  • [48] The regression of vascular changes in hypertension - calcium channel blocker or angiotensin-converting enzyme inhibitor?
    Czarnecka, Danuta
    Styczkiewicz, Katarzyna
    ARTERIAL HYPERTENSION, 2005, 9 (06): : 489 - 498
  • [49] Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension
    Redon, Josep
    Trenkwalder, Peter R. A.
    Barrios, Vivencio
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (02) : 155 - 164
  • [50] Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker
    Tanemoto, M
    Abe, T
    Obara, N
    Abe, M
    Satoh, F
    Ito, S
    HYPERTENSION RESEARCH, 2003, 26 (10) : 863 - 868